• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aytu BioPharma, Inc. - Common Stock (NQ:AYTU)

2.560 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aytu BioPharma, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results
February 03, 2026
Via ACCESS Newswire
News headline image
Aytu BioPharma Recaps Investor Day Held on January 20, 2026
January 20, 2026
Via ACCESS Newswire
News headline image
Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA
January 20, 2026
Via ACCESS Newswire
News headline image
Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
January 13, 2026
Via ACCESS Newswire
News headline image
Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City
January 12, 2026
Via ACCESS Newswire
News headline image
Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock
June 06, 2025
Via ACCESS Newswire
News headline image
Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results
February 12, 2025
Via ACCESS Newswire
News headline image
Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City
December 18, 2025
Via ACCESS Newswire
News headline image
Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults
December 15, 2025
Via ACCESS Newswire
News headline image
Aytu BioPharma to Participate in Noble Capital Markets 21st Annual Emerging Growth Equity Conference
November 24, 2025
Via ACCESS Newswire
News headline image
Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results
November 13, 2025
Via ACCESS Newswire
News headline image
Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025
November 05, 2025
Via ACCESS Newswire
News headline image
Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results
November 13, 2024
Via ACCESSWIRE
News headline image
Aytu BioPharma Announces Patent Term Extension for EXXUA(TM)
October 28, 2025
Via ACCESS Newswire
News headline image
Aytu BioPharma to Present at Upcoming October 2025 Conferences
October 10, 2025
Via ACCESS Newswire
News headline image
11 Company Presentations Today at The MicroCap Rodeo Conference
September 25, 2025
Via ACCESS Newswire
News headline image
Aytu BioPharma to Present at Upcoming September 2025 Conferences
September 24, 2025
Via ACCESS Newswire
News headline image
Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM)
September 23, 2025
Via ACCESS Newswire
News headline image
Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025
September 16, 2025
Via ACCESS Newswire
News headline image
Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM)
June 25, 2025
Via ACCESS Newswire
News headline image
Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)
June 23, 2025
Via ACCESS Newswire
News headline image
Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan
June 09, 2025
Via ACCESS Newswire
News headline image
Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States
June 06, 2025
Via ACCESS Newswire
News headline image
Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results
May 14, 2025
Via ACCESS Newswire
News headline image
Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025
May 07, 2025
Via ACCESS Newswire
News headline image
Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025
April 21, 2025
Via ACCESS Newswire
News headline image
Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025
February 05, 2025
Via ACCESS Newswire
News headline image
Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
January 06, 2025
Via ACCESSWIRE
News headline image
Aytu BioPharma Disclosure Notification
December 03, 2024
Via ACCESSWIRE
News headline image
Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)
November 22, 2024
Via ACCESSWIRE
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap